TeraRecon introduces iNtuition Review and iNtuition Share

TeraRecon launched iNtuition Review, iNtuition Enterprise Medical Viewer and iNtuition SHARE at the 14th congress of the Asian Oceanian Society of Radiology and 63rd annual scientific meeting of the Royal Australian and New Zealand College of Radiologists, held in Sydney, Aug. 30 to Sept. 2.

The software suite enhances the iNtuition portfolio with multi-modality review for advanced imaging such as cardiac and breast procedures, with enterprise distribution and image sharing capability, according to the company.

iNtuition Review expands iNtuition to support advanced professional multi-modality, multi-monitor review. Suited to the review of images related to conditions typically involving multi-modality imaging such as cardiac and breast, iNtuition Review provides a complement to PACS within radiology workflow, said TeraRecon. iNtuition Review includes functionality to create folders of cases for presentation in daily or weekly radiology conferences and multi-disciplinary meetings.

iNtuition Enterprise Medical Viewer (iEMV) builds upon the multi-modality review capability of iNtuition Review by providing a browser-based client which requires no download, no installation and no plugin. The viewer supports various browsers and integrates with the advanced visualization scene files from the iNtuition Client and multi-modality case presentations from iNtuition Review. iEMV is VMWare ready and virtualizable. On the client side, iEMV is equipped to integrate with EMR/HIS/PACS for enterprise access to image and non-image data.

iNtuition SHARE leverages iNtuition Uploader to make possible CD-free transport and distribution of images between medical facilities and peers, or patients. When a healthcare facility deploys an iNtuition SHARE server, it is able to offer free access to network upload of images to institutions that need to send images into the facility. Rather, it is possible to provide a link through which external facilities and patients can view and download images as required.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.